SOLO-1 Trial
PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer - The ASCO Post
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
Lynparza extended survival of ovarian cancer patients' < Pharma < 기사본문 - KBR
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis | NEJM
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
Maintenance strategies in phase III clinical trials assessing poly... | Download Scientific Diagram
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Olaparib Extends PFS in Ovarian Cancer in SOLO-1 Clinical Trial - Clinical Oncology News
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | NEJM
Advances in ovarian cancer, from biology to treatment | Nature Cancer
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - The Lancet Oncology
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
PARPi in OC - Ovarian Cancer PARPi Therapy - Module - PARP Inhibitors in Ovarian Cancer - Oncology - Clinical Care Options
Clinical Studies Overview | Orbactiv® (oritavancin) for injection
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
Efficacy of LYNPARZA® (olaparib) for Maintenance of BRCAm Advanced Ovarian Cancer
PARP inhibitors as first-line maintenance treatment for ovarian cancer: Translating the latest data to clinical practice - touchONCOLOGY
The latest clinical evidence on PARP inhibitor maintenance therapy - ppt download
Current status and future prospects of PARP inhibitor clinical trials | CMAR
